Prothena (PRTA) Competitors

$9.59 -0.17 (-1.74%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$9.85 +0.26 (+2.66%)

As of 03:59 AM Eastern

PRTA vs. ADPT, NBTX, BHC, OCUL, and ZLAB

Should you buy Prothena stock or one of its competitors? MarketBeat compares Prothena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prothena include Adaptive Biotechnologies (ADPT), Nanobiotix (NBTX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.

How does Prothena compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Prothena had 6 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 12 mentions for Prothena and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.41 beat Prothena's score of -0.47 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adaptive Biotechnologies has a net margin of -16.82% compared to Prothena's net margin of -260.92%. Adaptive Biotechnologies' return on equity of -40.06% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Prothena	-260.92%	-43.44%	-36.87%

Adaptive Biotechnologies has higher revenue and earnings than Prothena. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	7.34	-$59.50M	-$0.33	N/A
Prothena	$9.68M	51.86	-$244.09M	-$2.82	N/A

Adaptive Biotechnologies has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Prothena has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Adaptive Biotechnologies currently has a consensus price target of $19.57, suggesting a potential upside of 53.98%. Prothena has a consensus price target of $21.78, suggesting a potential upside of 127.09%. Given Prothena's higher possible upside, analysts plainly believe Prothena is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Summary

Adaptive Biotechnologies beats Prothena on 11 of the 17 factors compared between the two stocks.

How does Prothena compare to Nanobiotix?

Prothena (NASDAQ:PRTA) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Prothena has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Prothena had 11 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for Prothena and 1 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.42 beat Prothena's score of -0.47 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prothena currently has a consensus price target of $21.78, indicating a potential upside of 127.09%. Nanobiotix has a consensus price target of $26.67, indicating a potential downside of 46.11%. Given Prothena's higher possible upside, research analysts plainly believe Prothena is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

97.1% of Prothena shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nanobiotix has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Nanobiotix's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Nanobiotix	N/A	N/A	N/A

Nanobiotix has higher revenue and earnings than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	51.86	-$244.09M	-$2.82	N/A
Nanobiotix	$36.87M	65.11	-$27.11M	N/A	N/A

Summary

Nanobiotix beats Prothena on 9 of the 14 factors compared between the two stocks.

How does Prothena compare to Bausch Health Cos?

Prothena (NASDAQ:PRTA) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Prothena has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Bausch Health Cos has a net margin of -11.47% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Bausch Health Cos has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	51.86	-$244.09M	-$2.82	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Prothena presently has a consensus target price of $21.78, indicating a potential upside of 127.09%. Bausch Health Cos has a consensus target price of $8.00, indicating a potential upside of 49.39%. Given Prothena's stronger consensus rating and higher probable upside, research analysts plainly believe Prothena is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Prothena had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 12 mentions for Prothena and 7 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.00 beat Prothena's score of -0.47 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Prothena beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

How does Prothena compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Prothena has a net margin of -260.92% compared to Ocular Therapeutix's net margin of -558.24%. Prothena's return on equity of -43.44% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Prothena	-260.92%	-43.44%	-36.87%

Prothena has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	35.32	-$265.94M	-$1.46	N/A
Prothena	$9.68M	51.86	-$244.09M	-$2.82	N/A

In the previous week, Prothena had 8 more articles in the media than Ocular Therapeutix. MarketBeat recorded 12 mentions for Prothena and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.49 beat Prothena's score of -0.47 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Prothena has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Ocular Therapeutix presently has a consensus price target of $23.78, suggesting a potential upside of 183.74%. Prothena has a consensus price target of $21.78, suggesting a potential upside of 127.09%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Prothena beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does Prothena compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Zai Lab has higher revenue and earnings than Prothena. Zai Lab is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.65	-$175.54M	-$1.62	N/A
Prothena	$9.68M	51.86	-$244.09M	-$2.82	N/A

Zai Lab has a net margin of -39.29% compared to Prothena's net margin of -260.92%. Zai Lab's return on equity of -24.32% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Prothena	-260.92%	-43.44%	-36.87%

Zai Lab currently has a consensus target price of $45.83, suggesting a potential upside of 143.02%. Prothena has a consensus target price of $21.78, suggesting a potential upside of 127.09%. Given Zai Lab's stronger consensus rating and higher possible upside, research analysts clearly believe Zai Lab is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Zai Lab has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Prothena has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market.

In the previous week, Prothena had 7 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Prothena and 5 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.18 beat Prothena's score of -0.47 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zai Lab beats Prothena on 11 of the 16 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTA vs. The Competition

Export

Metric	Prothena	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$510.97M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-3.40	18.13	20.86	25.23
Price / Sales	51.86	275.82	552.57	80.03
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	1.84	6.57	9.67	6.63
Net Income	-$244.09M	$24.35M	$3.56B	$335.59M
7 Day Performance	1.70%	-2.53%	-1.67%	-1.20%
1 Month Performance	-12.02%	-3.55%	-2.63%	-1.16%
1 Year Performance	29.59%	53.51%	30.05%	28.10%

Prothena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTA Prothena	1.9282 of 5 stars	$9.59 -1.7%	$21.78 +127.1%	+33.6%	$510.97M	$9.68M	N/A	130
ADPT Adaptive Biotechnologies	3.5255 of 5 stars	$13.54 -2.0%	$20.00 +47.7%	+40.4%	$2.21B	$276.98M	N/A	790
NBTX Nanobiotix	1.4287 of 5 stars	$53.55 +17.7%	$26.67 -50.2%	+1,173.6%	$2.21B	$36.87M	N/A	100	Analyst Forecast High Trading Volume
BHC Bausch Health Cos	2.0632 of 5 stars	$5.36 -6.9%	$8.00 +49.4%	+14.5%	$2.15B	$10.27B	N/A	20,300
OCUL Ocular Therapeutix	3.5364 of 5 stars	$9.28 -3.8%	$23.78 +156.2%	+16.1%	$2.11B	$51.95M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTA) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Competitors

PRTA vs. ADPT, NBTX, BHC, OCUL, and ZLAB

How does Prothena compare to Adaptive Biotechnologies?

Summary

How does Prothena compare to Nanobiotix?

Summary

How does Prothena compare to Bausch Health Cos?

Summary

How does Prothena compare to Ocular Therapeutix?

Summary

How does Prothena compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Competitors

PRTA vs. ADPT, NBTX, BHC, OCUL, and ZLAB

How does Prothena compare to Adaptive Biotechnologies?

Do insiders & institutionals hold more shares of ADPT or PRTA?

Does the media favor ADPT or PRTA?

Is ADPT or PRTA more profitable?

Which has better valuation and earnings, ADPT or PRTA?

Which has more volatility & risk, ADPT or PRTA?

Do analysts recommend ADPT or PRTA?

Summary

How does Prothena compare to Nanobiotix?

Which has more volatility and risk, PRTA or NBTX?

Does the media refer more to PRTA or NBTX?

Do analysts rate PRTA or NBTX?

Do institutionals & insiders have more ownership in PRTA or NBTX?

Is PRTA or NBTX more profitable?

Which has better earnings and valuation, PRTA or NBTX?

Summary

How does Prothena compare to Bausch Health Cos?

Do institutionals and insiders believe in PRTA or BHC?

Which has more risk and volatility, PRTA or BHC?

Is PRTA or BHC more profitable?

Which has better valuation & earnings, PRTA or BHC?

Do analysts prefer PRTA or BHC?

Does the media favor PRTA or BHC?

Summary

How does Prothena compare to Ocular Therapeutix?

Is OCUL or PRTA more profitable?

Which has better earnings & valuation, OCUL or PRTA?

Does the media prefer OCUL or PRTA?

Which has more volatility and risk, OCUL or PRTA?

Do analysts recommend OCUL or PRTA?

Do institutionals and insiders hold more shares of OCUL or PRTA?

Summary

How does Prothena compare to Zai Lab?

Which has higher valuation & earnings, ZLAB or PRTA?

Is ZLAB or PRTA more profitable?

Do analysts recommend ZLAB or PRTA?

Which has more volatility & risk, ZLAB or PRTA?

Does the media prefer ZLAB or PRTA?

Do insiders and institutionals hold more shares of ZLAB or PRTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools